FGEN FibroGen, Inc

24.60
+0.2  (0.82%)
Previous Close 24.40
Open 24.25
Price To book 8.63
Market Cap 1.55B
Shares 63,160,000
Volume 354,309
Short Ratio 4.43
Av. Daily Volume 472,532

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from China trial released January 30, 2017. Primary endpoints met.
Roxadustat FG-4592
Anemia in chronic kidney disease
Phase 2 trial enrollment commenced January 2016. Continues to enroll as of November 2016.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 2 data due 3Q 2017.
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 2 ongoing. Data due late 2017 or 1Q 2018.
Pamrevlumab (FG-3019)
Pancreatic cancer

Latest News

  1. FIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy
  3. FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017
  4. Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen
  5. Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%
  6. FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  7. FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
  8. FibroGen (FGEN) Shares March Higher, Can It Continue?
  9. Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium
  10. Here Are Two Market Moving Biotech Catalysts To Watch This Week
  11. 6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
  12. Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.
  13. Will 2017 Be a Make or Break Year for FibroGen?
  14. FibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : December 23, 2016
  15. FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : December 22, 2016
  16. Why Akebia Therapeutics Inc Stock Zoomed Higher Today
  17. Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights
  18. ETFs with exposure to FibroGen, Inc. : December 16, 2016
  19. Is FibroGen Inc (FGEN) a Good Stock to Buy?
  20. GSK chases Astra with start of big anaemia drug trials